Big Pharma Split Corp Class A Capital Reinvestment Ratio
Big Pharma Split Corp Class A capital reinvestment ratio. Big Pharma Split Corp Class A (PRM) has a Capital Reinvestment Ratio of 0.00x as of December 2023, meaning it reinvests 0% of its operating cash flow (CA$11.86 Million) in capital expenditures (CA$3.00). Check PRM cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Big Pharma Split Corp Class A (2020–2023)
Capital reinvestment ratio of Big Pharma Split Corp Class A from 2020 to 2023. This chart tracks Big Pharma Split Corp Class A's Capital Reinvestment Ratio across 2 annual periods. Also explore Big Pharma Split Corp Class A (PRM) equity growth momentum to track the company's year-over-year net asset growth rate.
Big Pharma Split Corp Class A Capital Reinvestment Ratio by Year (2020–2023)
Big Pharma Split Corp Class A capital reinvestment ratio by year from 2020 to 2023. For the full cash flow conversion analysis, see Big Pharma Split Corp Class A cash conversion from operations.
| Year | Reinvestment Ratio | Operating CF (CAD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 0.00x | CA$11.86 Million | CA$3.00 | ▼ -63.3% |
| 2020 | 0.00x | CA$4.35 Million | CA$3.00 | — |